uuid stringlengths 4 8 | template_uuid stringclasses 40 values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 138 627 | execution_results stringlengths 2 1.14M | query_type stringclasses 2 values | sql_category stringclasses 26 values | bio_category stringclasses 14 values |
|---|---|---|---|---|---|---|---|---|
Q1.986 | Q1 | Is NOS1 a druggable gene? | There are currently no approved drugs targeting NOS1, but there are 2 drugs in clinical trials indicating that it may be a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%NOS1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_890', 'drugName': 'Tilarginine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NOS1 (ENSG00000089250), NOS2 (ENSG00000007171), NOS3 (ENSG00000164867)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1662', 'drugName': 'Tilarginine Acetate', 'drugIsApproved': False, 'newLinkedTargets_string': 'NOS1 (ENSG00000089250), NOS2 (ENSG00000007171), NOS3 (ENSG00000164867)', 'maxClinicalTrialPhase': 3}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.1507 | Q1 | Is TUBB6 a druggable gene? | There are currently 20 approved drugs which target TUBB6, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%TUBB6 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_1084', 'drugName': 'Brentuximab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1872', 'drugName': 'Belantamab Mafodotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4158', 'drugName': 'Tisotumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2339', 'drugName': 'Ixabepilone', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_974', 'drugName': 'Vinflunine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4166', 'drugName': 'Vinblastine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5756', 'drugName': 'Trastuzumab Emtansine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5604', 'drugName': 'Eribulin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2795', 'drugName': 'Enfortumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4743', 'drugName': 'Colchicine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_560', 'drugName': 'Polatuzumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_561', 'drugName': 'Polatuzumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1085', 'drugName': 'Brentuximab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6261', 'drugName': 'Vinblastine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2794', 'drugName': 'Enfortumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5140', 'drugName': 'Vincristine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4157', 'drugName': 'Tisotumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_762', 'drugName': 'Cabazitaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1267', 'drugName': 'Docetaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3175', 'drugName': 'Eribulin Mesylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2177', 'drugName': 'Docetaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2013', 'drugName': 'Paclitaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1871', 'drugName': 'Belantamab Mafodotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5757', 'drugName': 'Trastuzumab Emtansine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3353', 'drugName': 'Vincristine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2330', 'drugName': 'Vinorelbine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6364', 'drugName': 'Vinorelbine Tartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4123', 'drugName': 'Plinabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_429', 'drugName': 'Ang1005', 'drugIsApproved': False, 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3391', 'drugName': 'Fosbretabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1364', 'drugName': 'Ombrabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2595', 'drugName': 'Paclitaxel Poliglumex', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5727', 'drugName': 'Mirvetuximab Soravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3781', 'drugName': 'Telisotuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1224', 'drugName': 'Tusamitamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1225', 'drugName': 'Tusamitamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3782', 'drugName': 'Telisotuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3390', 'drugName': 'Fosbretabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_430', 'drugName': 'Ang1005', 'drugIsApproved': False, 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4860', 'drugName': 'Patupilone', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5728', 'drugName': 'Mirvetuximab Soravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_829', 'drugName': 'Larotaxel', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5370', 'drugName': 'Paclitaxel Docosahexaenoic Acid', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_186', 'drugName': 'Cantuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_187', 'drugName': 'Cantuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5922', 'drugName': 'Indusatumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4294', 'drugName': 'Arx-788', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2981', 'drugName': 'Plocabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3189', 'drugName': 'Sagopilone', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5837', 'drugName': 'Soblidotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4295', 'drugName': 'Arx-788', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4455', 'drugName': 'Ags-16C3F', 'drugIsApproved': False, 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4675', 'drugName': 'Milataxel', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4227', 'drugName': 'Verubulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4456', 'drugName': 'Ags-16C3F', 'drugIsApproved': False, 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2652', 'drugName': 'Ladiratuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4395', 'drugName': 'Fosbretabulin Tromethamine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3400', 'drugName': 'Abt-751', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBB3 (ENSG00000258947), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TUBB8B (ENSG00000173213)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6014', 'drugName': 'Praluzatamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4590', 'drugName': 'Epothilone D', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5130', 'drugName': 'Fosbretabulin Disodium', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5107', 'drugName': 'T-900607', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5627', 'drugName': 'Bms-275183', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3277', 'drugName': 'Davunetide', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3443', 'drugName': 'Lifastuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5974', 'drugName': 'Dolastatin-10', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5923', 'drugName': 'Indusatumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3444', 'drugName': 'Lifastuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4739', 'drugName': 'Lexibulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2653', 'drugName': 'Ladiratuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6314', 'drugName': 'Glembatumumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5310', 'drugName': 'Kos-1584', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6315', 'drugName': 'Glembatumumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4544', 'drugName': 'Lorvotuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4545', 'drugName': 'Lorvotuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6013', 'drugName': 'Praluzatamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5238', 'drugName': 'Sofituzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5239', 'drugName': 'Sofituzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6096', 'drugName': 'Pinatuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6097', 'drugName': 'Pinatuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_405', 'drugName': 'Asg-5Me', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_752', 'drugName': 'Vandortuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_831', 'drugName': 'Rg-7841', 'drugIsApproved': False, 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_753', 'drugName': 'Vandortuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1646', 'drugName': 'Azintuxizumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1647', 'drugName': 'Azintuxizumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_832', 'drugName': 'Rg-7841', 'drugIsApproved': False, 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1355', 'drugName': 'Pf-06263507', 'drugIsApproved': False, 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_406', 'drugName': 'Asg-5Me', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1356', 'drugName': 'Pf-06263507', 'drugIsApproved': False, 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2066', 'drugName': 'Aprutumab Ixadotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2067', 'drugName': 'Aprutumab Ixadotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_641', 'drugName': 'Rg-7600', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_642', 'drugName': 'Rg-7600', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5414', 'drugName': 'Rg-7636', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5415', 'drugName': 'Rg-7636', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5801', 'drugName': 'Enapotamab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5802', 'drugName': 'Enapotamab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6222', 'drugName': 'Bivatuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6223', 'drugName': 'Bivatuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.192 | Q1 | Is CCND1 a druggable gene? | There is 1 drug, Palbociclib, that targets CCND1, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CCND1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_2461', 'drugName': 'Palbociclib', 'drugIsApproved': True, 'newLinkedTargets_string': 'CCND1 (ENSG00000110092), CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2460', 'drugName': 'Palbociclib', 'drugIsApproved': True, 'newLinkedTargets_string': 'CCND1 (ENSG00000110092), CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_353', 'drugName': 'Briciclib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CCND1 (ENSG00000110092)', 'maxClinicalTrialPhase': 1}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.1147 | Q1 | Is PSCA a druggable gene? | There are currently no approved drugs targeting PSCA, but there is 1 drug in a clinical trial indicating that it may be a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PSCA %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_5916', 'drugName': 'Mk-4721', 'drugIsApproved': False, 'newLinkedTargets_string': 'PSCA (ENSG00000167653)', 'maxClinicalTrialPhase': 2}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.998 | Q1 | Is NPR1 a druggable gene? | There is 1 drug, Nesiritide, that targets NPR1, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%NPR1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_3389', 'drugName': 'Nesiritide', 'drugIsApproved': True, 'newLinkedTargets_string': 'NPR1 (ENSG00000169418)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2532', 'drugName': 'Carperitide', 'drugIsApproved': False, 'newLinkedTargets_string': 'NPR2 (ENSG00000159899), NPR1 (ENSG00000169418), NPR3 (ENSG00000113389)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_478', 'drugName': 'Pl-3994', 'drugIsApproved': False, 'newLinkedTargets_string': 'NPR1 (ENSG00000169418)', 'maxClinicalTrialPhase': 2}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.1500 | Q1 | Is TUBB a druggable gene? | There are currently 20 approved drugs which target TUBB, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%TUBB %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_1084', 'drugName': 'Brentuximab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1872', 'drugName': 'Belantamab Mafodotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4158', 'drugName': 'Tisotumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2339', 'drugName': 'Ixabepilone', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_974', 'drugName': 'Vinflunine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4166', 'drugName': 'Vinblastine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5756', 'drugName': 'Trastuzumab Emtansine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5604', 'drugName': 'Eribulin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2795', 'drugName': 'Enfortumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4743', 'drugName': 'Colchicine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_560', 'drugName': 'Polatuzumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_561', 'drugName': 'Polatuzumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1085', 'drugName': 'Brentuximab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6261', 'drugName': 'Vinblastine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2794', 'drugName': 'Enfortumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5140', 'drugName': 'Vincristine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4157', 'drugName': 'Tisotumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_762', 'drugName': 'Cabazitaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1267', 'drugName': 'Docetaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3175', 'drugName': 'Eribulin Mesylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2177', 'drugName': 'Docetaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2013', 'drugName': 'Paclitaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1871', 'drugName': 'Belantamab Mafodotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5757', 'drugName': 'Trastuzumab Emtansine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3353', 'drugName': 'Vincristine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2330', 'drugName': 'Vinorelbine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6364', 'drugName': 'Vinorelbine Tartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4123', 'drugName': 'Plinabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_429', 'drugName': 'Ang1005', 'drugIsApproved': False, 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3391', 'drugName': 'Fosbretabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1364', 'drugName': 'Ombrabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2595', 'drugName': 'Paclitaxel Poliglumex', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5727', 'drugName': 'Mirvetuximab Soravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3781', 'drugName': 'Telisotuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1224', 'drugName': 'Tusamitamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1225', 'drugName': 'Tusamitamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3782', 'drugName': 'Telisotuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3390', 'drugName': 'Fosbretabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_430', 'drugName': 'Ang1005', 'drugIsApproved': False, 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4860', 'drugName': 'Patupilone', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5728', 'drugName': 'Mirvetuximab Soravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_829', 'drugName': 'Larotaxel', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5370', 'drugName': 'Paclitaxel Docosahexaenoic Acid', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_186', 'drugName': 'Cantuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_187', 'drugName': 'Cantuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5922', 'drugName': 'Indusatumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4294', 'drugName': 'Arx-788', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2981', 'drugName': 'Plocabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3189', 'drugName': 'Sagopilone', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5837', 'drugName': 'Soblidotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4295', 'drugName': 'Arx-788', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4455', 'drugName': 'Ags-16C3F', 'drugIsApproved': False, 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4675', 'drugName': 'Milataxel', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4227', 'drugName': 'Verubulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4456', 'drugName': 'Ags-16C3F', 'drugIsApproved': False, 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2652', 'drugName': 'Ladiratuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4395', 'drugName': 'Fosbretabulin Tromethamine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3400', 'drugName': 'Abt-751', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBB3 (ENSG00000258947), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TUBB8B (ENSG00000173213)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6014', 'drugName': 'Praluzatamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4590', 'drugName': 'Epothilone D', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5130', 'drugName': 'Fosbretabulin Disodium', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5107', 'drugName': 'T-900607', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5627', 'drugName': 'Bms-275183', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3277', 'drugName': 'Davunetide', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3443', 'drugName': 'Lifastuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5974', 'drugName': 'Dolastatin-10', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5923', 'drugName': 'Indusatumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3444', 'drugName': 'Lifastuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4739', 'drugName': 'Lexibulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2653', 'drugName': 'Ladiratuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6314', 'drugName': 'Glembatumumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5310', 'drugName': 'Kos-1584', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6315', 'drugName': 'Glembatumumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4544', 'drugName': 'Lorvotuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4545', 'drugName': 'Lorvotuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6013', 'drugName': 'Praluzatamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5238', 'drugName': 'Sofituzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5239', 'drugName': 'Sofituzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6096', 'drugName': 'Pinatuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6097', 'drugName': 'Pinatuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_405', 'drugName': 'Asg-5Me', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_752', 'drugName': 'Vandortuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_831', 'drugName': 'Rg-7841', 'drugIsApproved': False, 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_753', 'drugName': 'Vandortuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1646', 'drugName': 'Azintuxizumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1647', 'drugName': 'Azintuxizumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_832', 'drugName': 'Rg-7841', 'drugIsApproved': False, 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1355', 'drugName': 'Pf-06263507', 'drugIsApproved': False, 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_406', 'drugName': 'Asg-5Me', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1356', 'drugName': 'Pf-06263507', 'drugIsApproved': False, 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2066', 'drugName': 'Aprutumab Ixadotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2067', 'drugName': 'Aprutumab Ixadotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_641', 'drugName': 'Rg-7600', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_642', 'drugName': 'Rg-7600', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5414', 'drugName': 'Rg-7636', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5415', 'drugName': 'Rg-7636', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5801', 'drugName': 'Enapotamab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5802', 'drugName': 'Enapotamab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6222', 'drugName': 'Bivatuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6223', 'drugName': 'Bivatuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.1283 | Q1 | Is RPS18 a druggable gene? | There is 1 drug, Ataluren, that targets RPS18, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%RPS18 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_3776', 'drugName': 'Ataluren', 'drugIsApproved': True, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4690', 'drugName': 'Mt-3724', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4448', 'drugName': 'Elx-02', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4691', 'drugName': 'Mt-3724', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2146', 'drugName': 'Dorlimomab Aritox', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_437', 'drugName': 'Cycloheximide', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': -1}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.610 | Q1 | Is HSP90AB1 a druggable gene? | There are currently no approved drugs targeting HSP90AB1, but there are 10 drugs in clinical trials indicating that it may be a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%HSP90AB1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_1279', 'drugName': 'Retaspimycin Hydrochloride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2657', 'drugName': 'Tanespimycin', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5251', 'drugName': 'Cd24Fc', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384), SIGLEC10 (ENSG00000142512), HMGB1 (ENSG00000189403), HSPA1A (ENSG00000204389), HSPA1B (ENSG00000204388)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5252', 'drugName': 'Cd24Fc', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384), SIGLEC10 (ENSG00000142512), HMGB1 (ENSG00000189403), HSPA1A (ENSG00000204389), HSPA1B (ENSG00000204388)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3977', 'drugName': 'Retaspimycin', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5250', 'drugName': 'Cd24Fc', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384), SIGLEC10 (ENSG00000142512), HMGB1 (ENSG00000189403), HSPA1A (ENSG00000204389), HSPA1B (ENSG00000204388)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1926', 'drugName': 'Ganetespib', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5249', 'drugName': 'Cd24Fc', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384), SIGLEC10 (ENSG00000142512), HMGB1 (ENSG00000189403), HSPA1A (ENSG00000204389), HSPA1B (ENSG00000204388)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4328', 'drugName': 'Luminespib', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2883', 'drugName': 'Snx 5422', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_325', 'drugName': 'Onalespib', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3448', 'drugName': 'Biib021', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5099', 'drugName': 'Alvespimycin', 'drugIsApproved': False, 'newLinkedTargets_string': 'HSP90AA1 (ENSG00000080824), HSP90AB1 (ENSG00000096384)', 'maxClinicalTrialPhase': 2}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.182 | Q1 | Is CASP7 a druggable gene? | There are currently no approved drugs targeting CASP7, but there is 1 drug in a clinical trial indicating that it may be a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CASP7 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_45', 'drugName': 'Emricasan', 'drugIsApproved': False, 'newLinkedTargets_string': 'CASP4 (ENSG00000196954), CASP9 (ENSG00000132906), CASP3 (ENSG00000164305), CASP5 (ENSG00000137757), CASP6 (ENSG00000138794), CASP7 (ENSG00000165806), CASP8 (ENSG00000064012), CASP1 (ENSG00000137752), CASP2 (ENSG00000106144), CASP10 (ENSG00000003400), CASP14 (ENSG00000105141), CASP12 (ENSG00000204403)', 'maxClinicalTrialPhase': 2}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.303 | Q1 | Is COL5A2 a druggable gene? | There are currently 2 approved drugs which target COL5A2, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%COL5A2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_5818', 'drugName': 'Ocriplasmin', 'drugIsApproved': True, 'newLinkedTargets_string': 'FN1 (ENSG00000115414), COL1A2 (ENSG00000164692), COL1A1 (ENSG00000108821), COL2A1 (ENSG00000139219), COL3A1 (ENSG00000168542), COL4A1 (ENSG00000187498), COL5A1 (ENSG00000130635), COL6A1 (ENSG00000142156), COL11A1 (ENSG00000060718), COL15A1 (ENSG00000204291), COL18A1 (ENSG00000182871), COL24A1 (ENSG00000171502), COL27A1 (ENSG00000196739), COL28A1 (ENSG00000215018), COL4A2 (ENSG00000134871), COL5A2 (ENSG00000204262), COL6A2 (ENSG00000142173), COL11A2 (ENSG00000204248), COL4A3 (ENSG00000169031), COL5A3 (ENSG00000080573), COL6A3 (ENSG00000163359), COL4A4 (ENSG00000081052), COL4A5 (ENSG00000188153), COL6A5 (ENSG00000172752), COL4A6 (ENSG00000197565), COL6A6 (ENSG00000206384), LAMA1 (ENSG00000101680), LAMA2 (ENSG00000196569), LAMA3 (ENSG00000053747), LAMA4 (ENSG00000112769), LAMA5 (ENSG00000130702), LAMB1 (ENSG00000091136), LAMB2 (ENSG00000172037), LAMB3 (ENSG00000196878), LAMB4 (ENSG00000091128), LAMC1 (ENSG00000135862), LAMC2 (ENSG00000058085), LAMC3 (ENSG00000050555)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1275', 'drugName': 'Collagenase Clostridium Histolyticum', 'drugIsApproved': True, 'newLinkedTargets_string': 'COL1A2 (ENSG00000164692), COL1A1 (ENSG00000108821), COL2A1 (ENSG00000139219), COL3A1 (ENSG00000168542), COL4A1 (ENSG00000187498), COL5A1 (ENSG00000130635), COL6A1 (ENSG00000142156), COL11A1 (ENSG00000060718), COL15A1 (ENSG00000204291), COL18A1 (ENSG00000182871), COL24A1 (ENSG00000171502), COL27A1 (ENSG00000196739), COL28A1 (ENSG00000215018), COL4A2 (ENSG00000134871), COL5A2 (ENSG00000204262), COL6A2 (ENSG00000142173), COL11A2 (ENSG00000204248), COL4A3 (ENSG00000169031), COL5A3 (ENSG00000080573), COL6A3 (ENSG00000163359), COL4A4 (ENSG00000081052), COL4A5 (ENSG00000188153), COL6A5 (ENSG00000172752), COL4A6 (ENSG00000197565), COL6A6 (ENSG00000206384)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5820', 'drugName': 'Ocriplasmin', 'drugIsApproved': True, 'newLinkedTargets_string': 'FN1 (ENSG00000115414), COL1A2 (ENSG00000164692), COL1A1 (ENSG00000108821), COL2A1 (ENSG00000139219), COL3A1 (ENSG00000168542), COL4A1 (ENSG00000187498), COL5A1 (ENSG00000130635), COL6A1 (ENSG00000142156), COL11A1 (ENSG00000060718), COL15A1 (ENSG00000204291), COL18A1 (ENSG00000182871), COL24A1 (ENSG00000171502), COL27A1 (ENSG00000196739), COL28A1 (ENSG00000215018), COL4A2 (ENSG00000134871), COL5A2 (ENSG00000204262), COL6A2 (ENSG00000142173), COL11A2 (ENSG00000204248), COL4A3 (ENSG00000169031), COL5A3 (ENSG00000080573), COL6A3 (ENSG00000163359), COL4A4 (ENSG00000081052), COL4A5 (ENSG00000188153), COL6A5 (ENSG00000172752), COL4A6 (ENSG00000197565), COL6A6 (ENSG00000206384), LAMA1 (ENSG00000101680), LAMA2 (ENSG00000196569), LAMA3 (ENSG00000053747), LAMA4 (ENSG00000112769), LAMA5 (ENSG00000130702), LAMB1 (ENSG00000091136), LAMB2 (ENSG00000172037), LAMB3 (ENSG00000196878), LAMB4 (ENSG00000091128), LAMC1 (ENSG00000135862), LAMC2 (ENSG00000058085), LAMC3 (ENSG00000050555)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5819', 'drugName': 'Ocriplasmin', 'drugIsApproved': True, 'newLinkedTargets_string': 'FN1 (ENSG00000115414), COL1A2 (ENSG00000164692), COL1A1 (ENSG00000108821), COL2A1 (ENSG00000139219), COL3A1 (ENSG00000168542), COL4A1 (ENSG00000187498), COL5A1 (ENSG00000130635), COL6A1 (ENSG00000142156), COL11A1 (ENSG00000060718), COL15A1 (ENSG00000204291), COL18A1 (ENSG00000182871), COL24A1 (ENSG00000171502), COL27A1 (ENSG00000196739), COL28A1 (ENSG00000215018), COL4A2 (ENSG00000134871), COL5A2 (ENSG00000204262), COL6A2 (ENSG00000142173), COL11A2 (ENSG00000204248), COL4A3 (ENSG00000169031), COL5A3 (ENSG00000080573), COL6A3 (ENSG00000163359), COL4A4 (ENSG00000081052), COL4A5 (ENSG00000188153), COL6A5 (ENSG00000172752), COL4A6 (ENSG00000197565), COL6A6 (ENSG00000206384), LAMA1 (ENSG00000101680), LAMA2 (ENSG00000196569), LAMA3 (ENSG00000053747), LAMA4 (ENSG00000112769), LAMA5 (ENSG00000130702), LAMB1 (ENSG00000091136), LAMB2 (ENSG00000172037), LAMB3 (ENSG00000196878), LAMB4 (ENSG00000091128), LAMC1 (ENSG00000135862), LAMC2 (ENSG00000058085), LAMC3 (ENSG00000050555)', 'maxClinicalTrialPhase': 4}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.499 | Q1 | Is GABRB1 a druggable gene? | There are currently 70 approved drugs which target GABRB1, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%GABRB1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_3142', 'drugName': 'Lorazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4503', 'drugName': 'Zolpidem', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRG2 (ENSG00000113327), GABRB1 (ENSG00000163288)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4750', 'drugName': 'Clorazepic Acid', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2327', 'drugName': 'Pentobarbital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4460', 'drugName': 'Alprazolam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5114', 'drugName': 'Etomidate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_143', 'drugName': 'Meprobamate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5904', 'drugName': 'Zolpidem Tartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRG2 (ENSG00000113327), GABRB1 (ENSG00000163288)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5981', 'drugName': 'Clobazam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6336', 'drugName': 'Flurazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6147', 'drugName': 'Clotiazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6371', 'drugName': 'Secobarbital Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1496', 'drugName': 'Clonazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1047', 'drugName': 'Acamprosate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5701', 'drugName': 'Triazolam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4122', 'drugName': 'Halazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1108', 'drugName': 'Temazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1441', 'drugName': 'Methyprylon', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1494', 'drugName': 'Thiopental', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4008', 'drugName': 'Midazolam Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2188', 'drugName': 'Midazolam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6282', 'drugName': 'Estazolam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1439', 'drugName': 'Diazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5294', 'drugName': 'Eszopiclone', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5041', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2024', 'drugName': 'Brexanolone', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1369', 'drugName': 'Ganaxolone', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5600', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_422', 'drugName': 'Butabarbital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3050', 'drugName': 'Butabarbital Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5547', 'drugName': 'Secobarbital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2918', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_314', 'drugName': 'Methohexital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2854', 'drugName': 'Chlordiazepoxide Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4143', 'drugName': 'Methohexital Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_214', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_653', 'drugName': 'Flurazepam Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_757', 'drugName': 'Pentobarbital Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3020', 'drugName': 'Glutethimide', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_210', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4971', 'drugName': 'Thiopental Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4830', 'drugName': 'Prazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_341', 'drugName': 'Metharbital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_215', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2585', 'drugName': 'Triclofos Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2623', 'drugName': 'Talbutal', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3021', 'drugName': 'Triclofos', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3421', 'drugName': 'Thiamylal Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5165', 'drugName': 'Thiamylal', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3415', 'drugName': 'Butalbital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3979', 'drugName': 'Quazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1332', 'drugName': 'Flunitrazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2025', 'drugName': 'Methaqualone Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3278', 'drugName': 'Tetrazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4173', 'drugName': 'Methaqualone', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4253', 'drugName': 'Flumazenil', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2196', 'drugName': 'Methoxyflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5043', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2275', 'drugName': 'Oxazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5594', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5595', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5596', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5597', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5598', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5599', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_212', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3261', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3262', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3263', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3264', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3265', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3266', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3267', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5042', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2919', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2920', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2921', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2922', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2923', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2924', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1046', 'drugName': 'Acamprosate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_216', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5037', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5038', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5039', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_164', 'drugName': 'Acamprosate Calcium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_163', 'drugName': 'Acamprosate Calcium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_213', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_211', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5040', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1800', 'drugName': 'Remimazolam Besylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3115', 'drugName': 'Propofol', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4453', 'drugName': 'Chlordiazepoxide', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2197', 'drugName': 'Methoxyflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3380', 'drugName': 'Remimazolam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5271', 'drugName': 'Clorazepate Dipotassium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3295', 'drugName': 'Ethchlorvynol', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2287', 'drugName': 'Clomethiazole', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6180', 'drugName': 'Zopiclone', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRA3 (ENSG00000011677), GABRB1 (ENSG00000163288), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3395', 'drugName': 'Zaleplon', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRG2 (ENSG00000113327), GABRB1 (ENSG00000163288)', 'maxClinicalTrialPhase': 4}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.1324 | Q1 | Is RYR3 a druggable gene? | There are currently 2 approved drugs which target RYR3, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%RYR3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_4505', 'drugName': 'Dantrolene Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'RYR3 (ENSG00000198838), RYR1 (ENSG00000196218)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4504', 'drugName': 'Dantrolene Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'RYR3 (ENSG00000198838), RYR1 (ENSG00000196218)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3510', 'drugName': 'Dantrolene', 'drugIsApproved': True, 'newLinkedTargets_string': 'RYR3 (ENSG00000198838), RYR1 (ENSG00000196218)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3509', 'drugName': 'Dantrolene', 'drugIsApproved': True, 'newLinkedTargets_string': 'RYR3 (ENSG00000198838), RYR1 (ENSG00000196218)', 'maxClinicalTrialPhase': 4}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.1288 | Q1 | Is RPS23 a druggable gene? | There is 1 drug, Ataluren, that targets RPS23, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%RPS23 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_3776', 'drugName': 'Ataluren', 'drugIsApproved': True, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4690', 'drugName': 'Mt-3724', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4448', 'drugName': 'Elx-02', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4691', 'drugName': 'Mt-3724', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2146', 'drugName': 'Dorlimomab Aritox', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_437', 'drugName': 'Cycloheximide', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': -1}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.1268 | Q1 | Is RPL7 a druggable gene? | There is 1 drug, Ataluren, that targets RPL7, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%RPL7 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_3776', 'drugName': 'Ataluren', 'drugIsApproved': True, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4690', 'drugName': 'Mt-3724', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4448', 'drugName': 'Elx-02', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4691', 'drugName': 'Mt-3724', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2146', 'drugName': 'Dorlimomab Aritox', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_437', 'drugName': 'Cycloheximide', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': -1}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.520 | Q1 | Is GIPR a druggable gene? | There is 1 drug, Tirzepatide, that targets GIPR, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%GIPR %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_5134', 'drugName': 'Tirzepatide', 'drugIsApproved': True, 'newLinkedTargets_string': 'GIPR (ENSG00000010310), GLP1R (ENSG00000112164)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5135', 'drugName': 'Tirzepatide', 'drugIsApproved': True, 'newLinkedTargets_string': 'GIPR (ENSG00000010310), GLP1R (ENSG00000112164)', 'maxClinicalTrialPhase': 4}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.1075 | Q1 | Is PIK3CA a druggable gene? | There are currently 3 approved drugs which target PIK3CA, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PIK3CA %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_722', 'drugName': 'Alpelisib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1214', 'drugName': 'Copanlisib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2314', 'drugName': 'Copanlisib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1213', 'drugName': 'Copanlisib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2313', 'drugName': 'Copanlisib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5564', 'drugName': 'Dactolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5563', 'drugName': 'Dactolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4060', 'drugName': 'Taselisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4797', 'drugName': 'Gedatolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3247', 'drugName': 'Buparlisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4798', 'drugName': 'Gedatolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5452', 'drugName': 'Serabelisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2174', 'drugName': 'Bgt-226', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1973', 'drugName': 'Sf-1126', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2175', 'drugName': 'Bgt-226', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1972', 'drugName': 'Sf-1126', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2180', 'drugName': 'Sonolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_15', 'drugName': 'Bgt-226', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_33', 'drugName': 'Pictilisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_233', 'drugName': 'Azd-6482', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1740', 'drugName': 'Paxalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5279', 'drugName': 'Pilaralisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2320', 'drugName': 'Samotolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2801', 'drugName': 'Voxtalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3171', 'drugName': 'Pf-04691502', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_138', 'drugName': 'Zstk-474', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5651', 'drugName': 'Inavolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4987', 'drugName': 'Apitolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_129', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4986', 'drugName': 'Apitolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_130', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_14', 'drugName': 'Bgt-226', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_128', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_127', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2319', 'drugName': 'Samotolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2802', 'drugName': 'Voxtalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3170', 'drugName': 'Pf-04691502', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5191', 'drugName': 'Bay-1082439', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879), PIK3CB (ENSG00000051382)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6376', 'drugName': 'Pki-179', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3CA (ENSG00000121879)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2871', 'drugName': 'Wx-037', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4026', 'drugName': 'Pwt-33587', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5206', 'drugName': 'Izorlisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4027', 'drugName': 'Pwt-33587', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5867', 'drugName': 'Puquitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), PDGFRB (ENSG00000113721), EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5866', 'drugName': 'Puquitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), PDGFRB (ENSG00000113721), EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5396', 'drugName': 'Pwt-33579', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3CA (ENSG00000121879)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5892', 'drugName': 'Recilisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2427', 'drugName': 'Panulisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ACVRL1 (ENSG00000139567), MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5397', 'drugName': 'Pwt-33579', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3CA (ENSG00000121879)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5192', 'drugName': 'Bay-1082439', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879), PIK3CB (ENSG00000051382)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5868', 'drugName': 'Puquitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), PDGFRB (ENSG00000113721), EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4506', 'drugName': 'Vs-5584', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2425', 'drugName': 'Panulisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ACVRL1 (ENSG00000139567), MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5351', 'drugName': 'Omipalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2426', 'drugName': 'Panulisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ACVRL1 (ENSG00000139567), MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6375', 'drugName': 'Pki-179', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3CA (ENSG00000121879)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_407', 'drugName': 'Ink-1117', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4507', 'drugName': 'Vs-5584', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5865', 'drugName': 'Puquitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), PDGFRB (ENSG00000113721), EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4622', 'drugName': 'Ds-7423', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_824', 'drugName': 'Gsk-1059615', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4623', 'drugName': 'Ds-7423', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5350', 'drugName': 'Omipalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.478 | Q1 | Is FOLH1 a druggable gene? | There are currently 2 approved drugs which target FOLH1, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%FOLH1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_5876', 'drugName': 'Lutetium Lu 177 Vipivotide Tetraxetan', 'drugIsApproved': True, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5373', 'drugName': 'Vipivotide Tetraxetan Lutetium', 'drugIsApproved': True, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6225', 'drugName': 'Huj591 177Lu', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4874', 'drugName': 'J591 177Lu', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3612', 'drugName': 'Mdx-070', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_500', 'drugName': 'Yttrium Y 90 Capromab Pendetide', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4279', 'drugName': 'Huj591 111In', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5127', 'drugName': 'Mln-2704', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1090', 'drugName': 'Cyt-500 177Lu', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'maxClinicalTrialPhase': 1}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.159 | Q1 | Is CACNB4 a druggable gene? | There are currently 9 approved drugs which target CACNB4, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CACNB4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_142', 'drugName': 'Gabapentin', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4565', 'drugName': 'Bepridil Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6291', 'drugName': 'Terodiline', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM4 (ENSG00000180720), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072), CHRM5 (ENSG00000184984), CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6292', 'drugName': 'Terodiline', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM4 (ENSG00000180720), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072), CHRM5 (ENSG00000184984), CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_311', 'drugName': 'Terodiline Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM4 (ENSG00000180720), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072), CHRM5 (ENSG00000184984), CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4910', 'drugName': 'Bepridil', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2991', 'drugName': 'Pregabalin', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1320', 'drugName': 'Phloroglucinol', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_310', 'drugName': 'Terodiline Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM4 (ENSG00000180720), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072), CHRM5 (ENSG00000184984), CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1799', 'drugName': 'Suloctidil', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4133', 'drugName': 'Gabapentin Enacarbil', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2281', 'drugName': 'Imagabalin', 'drugIsApproved': False, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2254', 'drugName': 'Atagabalin', 'drugIsApproved': False, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 2}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.1204 | Q1 | Is PTPN11 a druggable gene? | There are currently no approved drugs targeting PTPN11, but there is 1 drug in a clinical trial indicating that it may be a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PTPN11 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_6363', 'drugName': 'Batoprotafib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTPN11 (ENSG00000179295)', 'maxClinicalTrialPhase': 1}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.17 | Q1 | Is ADA a druggable gene? | There is 1 drug, Pentostatin, that targets ADA, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ADA %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_251', 'drugName': 'Pentostatin', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADA (ENSG00000196839)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5186', 'drugName': 'Coformycin', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADA (ENSG00000196839)', 'maxClinicalTrialPhase': 2}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q1.1078 | Q1 | Is PIK3CG a druggable gene? | There is 1 drug, Duvelisib, that targets PIK3CG, indicating that it is a druggable gene. | SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PIK3CG %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
| [{'UUID': 'DrugGeneTargets_v2_1892', 'drugName': 'Duvelisib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1893', 'drugName': 'Duvelisib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3247', 'drugName': 'Buparlisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4797', 'drugName': 'Gedatolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5563', 'drugName': 'Dactolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4798', 'drugName': 'Gedatolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5564', 'drugName': 'Dactolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4060', 'drugName': 'Taselisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1219', 'drugName': 'Tenalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2801', 'drugName': 'Voxtalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4986', 'drugName': 'Apitolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2180', 'drugName': 'Sonolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2174', 'drugName': 'Bgt-226', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_15', 'drugName': 'Bgt-226', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1973', 'drugName': 'Sf-1126', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_33', 'drugName': 'Pictilisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5279', 'drugName': 'Pilaralisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1485', 'drugName': 'Tg100-115', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_14', 'drugName': 'Bgt-226', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_138', 'drugName': 'Zstk-474', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2175', 'drugName': 'Bgt-226', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4987', 'drugName': 'Apitolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3170', 'drugName': 'Pf-04691502', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2320', 'drugName': 'Samotolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2319', 'drugName': 'Samotolisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1740', 'drugName': 'Paxalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3171', 'drugName': 'Pf-04691502', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1972', 'drugName': 'Sf-1126', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_233', 'drugName': 'Azd-6482', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2802', 'drugName': 'Voxtalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4113', 'drugName': 'Eganelisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1484', 'drugName': 'Tg100-115', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1220', 'drugName': 'Tenalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2647', 'drugName': 'Rp-6530', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4880', 'drugName': 'Cal-263', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CD (ENSG00000171608), PIK3CG (ENSG00000105851)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5867', 'drugName': 'Puquitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), PDGFRB (ENSG00000113721), EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5866', 'drugName': 'Puquitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), PDGFRB (ENSG00000113721), EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5865', 'drugName': 'Puquitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), PDGFRB (ENSG00000113721), EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2427', 'drugName': 'Panulisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ACVRL1 (ENSG00000139567), MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2426', 'drugName': 'Panulisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ACVRL1 (ENSG00000139567), MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2425', 'drugName': 'Panulisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ACVRL1 (ENSG00000139567), MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2648', 'drugName': 'Rp-6530', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CG (ENSG00000105851), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_824', 'drugName': 'Gsk-1059615', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4506', 'drugName': 'Vs-5584', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4507', 'drugName': 'Vs-5584', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2871', 'drugName': 'Wx-037', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4622', 'drugName': 'Ds-7423', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4623', 'drugName': 'Ds-7423', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5206', 'drugName': 'Izorlisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4879', 'drugName': 'Cal-263', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CD (ENSG00000171608), PIK3CG (ENSG00000105851)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5350', 'drugName': 'Omipalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5868', 'drugName': 'Puquitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), PDGFRB (ENSG00000113721), EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5351', 'drugName': 'Omipalisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5892', 'drugName': 'Recilisib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4026', 'drugName': 'Pwt-33587', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4027', 'drugName': 'Pwt-33587', 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'maxClinicalTrialPhase': 1}] | general | Similarity Search, Order By, Distinct | Approval Status, Genetic Target |
Q10.589 | Q10 | Are there any PCAT6 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within PCAT6 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'PCAT6' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1868 | Q10 | Are there any SCN3A SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within SCN3A that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'SCN3A' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1061 | Q10 | Are there any PPP3R1 SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within PPP3R1 that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'PPP3R1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1084 | Q10 | Are there any TNPO2 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within TNPO2 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'TNPO2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.925 | Q10 | Are there any RP11-259G18.2 SNPs that have a statistically significant association with Parkinson's Disease? | Yes, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there is at least 14 RP11-259G18.2 SNP that are significantly associatied with Parkinson's Disease:
• rs17661015 (GWAS p-value: 4.30e-21; b-value: -0.2573)
• rs9468 (GWAS p-value: 5.02e-21; b-value: -0.2371)
• rs62061822 (GWAS p-value: 5.27e-21; b-value: -0.2539)
• rs55974014 (GWAS p-value: 8.84e-21; b-value: -0.2571)
• rs62055938 (GWAS p-value: 9.24e-21; b-value: -0.2523)
• rs17763086 (GWAS p-value: 2.06e-20; b-value: -0.25)
• rs62055888 (GWAS p-value: 2.23e-20; b-value: -0.2507)
• rs62056812 (GWAS p-value: 7.62e-20; b-value: -0.2462)
• rs2532233 (GWAS p-value: 1.47e-19; b-value: -0.2325)
• rs578109777 (GWAS p-value: 1.62e-19; b-value: -0.2485) | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'RP11-259G18.2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [{'UUID': 'NDD_SMR_genes_all_update_text_1679567', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs17661015', 'p_GWAS': 4.3048099999999995e-21, 'b_GWAS': -0.2573}, {'UUID': 'NDD_SMR_genes_all_update_text_1451664', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs9468', 'p_GWAS': 5.021668e-21, 'b_GWAS': -0.2371}, {'UUID': 'NDD_SMR_genes_all_update_text_1594925', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs62061822', 'p_GWAS': 5.267548e-21, 'b_GWAS': -0.2539}, {'UUID': 'NDD_SMR_genes_all_update_text_1730066', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs55974014', 'p_GWAS': 8.840428e-21, 'b_GWAS': -0.2571}, {'UUID': 'NDD_SMR_genes_all_update_text_1168836', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs55974014', 'p_GWAS': 8.840428e-21, 'b_GWAS': -0.2571}, {'UUID': 'NDD_SMR_genes_all_update_text_1476428', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs62055938', 'p_GWAS': 9.237313e-21, 'b_GWAS': -0.2523}, {'UUID': 'NDD_SMR_genes_all_update_text_1191173', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs17763086', 'p_GWAS': 2.058553e-20, 'b_GWAS': -0.25}, {'UUID': 'NDD_SMR_genes_all_update_text_1262226', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs62055888', 'p_GWAS': 2.2256339999999998e-20, 'b_GWAS': -0.2507}, {'UUID': 'NDD_SMR_genes_all_update_text_1710351', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs62056812', 'p_GWAS': 7.615824e-20, 'b_GWAS': -0.2462}, {'UUID': 'NDD_SMR_genes_all_update_text_1564786', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs2532233', 'p_GWAS': 1.473642e-19, 'b_GWAS': -0.2325}, {'UUID': 'NDD_SMR_genes_all_update_text_491154', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs578109777', 'p_GWAS': 1.6197019999999998e-19, 'b_GWAS': -0.2485}, {'UUID': 'NDD_SMR_genes_all_update_text_1386992', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs199456', 'p_GWAS': 3.118986e-19, 'b_GWAS': -0.2268}, {'UUID': 'NDD_SMR_genes_all_update_text_1328935', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs2532363', 'p_GWAS': 3.820893e-19, 'b_GWAS': -0.2468}, {'UUID': 'NDD_SMR_genes_all_update_text_1281356', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs199533', 'p_GWAS': 1.090724e-18, 'b_GWAS': -0.2224}, {'UUID': 'NDD_SMR_genes_all_update_text_1462896', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs199533', 'p_GWAS': 1.090724e-18, 'b_GWAS': -0.2224}, {'UUID': 'NDD_SMR_genes_all_update_text_1488141', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs199533', 'p_GWAS': 1.090724e-18, 'b_GWAS': -0.2224}, {'UUID': 'NDD_SMR_genes_all_update_text_1603777', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs199533', 'p_GWAS': 1.090724e-18, 'b_GWAS': -0.2224}, {'UUID': 'NDD_SMR_genes_all_update_text_1640223', 'Gene': 'RP11-259G18.2', 'topRSID': 'rs199528', 'p_GWAS': 2.740945e-16, 'b_GWAS': 0.2177}] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.73 | Q10 | Are there any AC106801.1 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within AC106801.1 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'AC106801.1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.435 | Q10 | Are there any TENC1 SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within TENC1 that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'TENC1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.911 | Q10 | Are there any CATSPERB SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within CATSPERB that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'CATSPERB' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.922 | Q10 | Are there any TSC2 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within TSC2 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'TSC2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1679 | Q10 | Are there any AC006262.6 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within AC006262.6 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'AC006262.6' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1272 | Q10 | Are there any SLC45A3 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within SLC45A3 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'SLC45A3' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1094 | Q10 | Are there any APOC1P1 SNPs that have a statistically significant association with Alzheimer's Disease? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there is at least 1 APOC1P1 SNP that are significantly associatied with Alzheimer's Disease:
• rs5112 (GWAS p-value: 1.03e-24; b-value: -0.0975) | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'APOC1P1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [{'UUID': 'NDD_SMR_genes_all_update_text_1466878', 'Gene': 'APOC1P1', 'topRSID': 'rs5112', 'p_GWAS': 1.032731e-24, 'b_GWAS': -0.0975}] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.389 | Q10 | Are there any MAT1A SNPs that have a statistically significant association with Alzheimer's Disease? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are at least 5 MAT1A SNPs that are significantly associatied with Alzheimer's Disease:
• rs10749551 (GWAS p-value: 6.54e-09; b-value: 0.0499)
• rs10788545 (GWAS p-value: 2.91e-08; b-value: 0.0477)
• rs1890578 (GWAS p-value: 9.24e-09; b-value: 0.0494)
• rs9420359 (GWAS p-value: 8.62e-09; b-value: 0.0495)
• rs3120976 (GWAS p-value: 4.33e-08; b-value: -0.0471) | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'MAT1A' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [{'UUID': 'NDD_SMR_genes_all_update_text_85765', 'Gene': 'MAT1A', 'topRSID': 'rs10749551', 'p_GWAS': 6.540141e-09, 'b_GWAS': 0.0499}, {'UUID': 'NDD_SMR_genes_all_update_text_85768', 'Gene': 'MAT1A', 'topRSID': 'rs9420359', 'p_GWAS': 8.622531e-09, 'b_GWAS': 0.0495}, {'UUID': 'NDD_SMR_genes_all_update_text_572621', 'Gene': 'MAT1A', 'topRSID': 'rs1890578', 'p_GWAS': 9.236419e-09, 'b_GWAS': -0.0494}, {'UUID': 'NDD_SMR_genes_all_update_text_85767', 'Gene': 'MAT1A', 'topRSID': 'rs1890578', 'p_GWAS': 9.236419e-09, 'b_GWAS': 0.0494}, {'UUID': 'NDD_SMR_genes_all_update_text_85766', 'Gene': 'MAT1A', 'topRSID': 'rs10788545', 'p_GWAS': 2.914253e-08, 'b_GWAS': 0.0477}, {'UUID': 'NDD_SMR_genes_all_update_text_1105560', 'Gene': 'MAT1A', 'topRSID': 'rs3120976', 'p_GWAS': 4.332228e-08, 'b_GWAS': -0.0471}] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.841 | Q10 | Are there any RP11-293E1.1 SNPs that have a statistically significant association with Alzheimer's Disease? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there is at least 1 RP11-293E1.1 SNP that are significantly associatied with Alzheimer's Disease:
• rs62062286 (GWAS p-value: 2.12e-08; b-value: -0.0549) | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'RP11-293E1.1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [{'UUID': 'NDD_SMR_genes_all_update_text_1203005', 'Gene': 'RP11-293E1.1', 'topRSID': 'rs62062286', 'p_GWAS': 2.118427e-08, 'b_GWAS': -0.0549}] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.774 | Q10 | Are there any SBF2 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within SBF2 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'SBF2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1805 | Q10 | Are there any GAD1 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within GAD1 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'GAD1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1992 | Q10 | Are there any CLASRP SNPs that have a statistically significant association with Alzheimer's Disease? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there is at least 1 CLASRP SNP that are significantly associatied with Alzheimer's Disease:
• rs1560725 (GWAS p-value: 1.31e-08; b-value: 0.0506) | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'CLASRP' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [{'UUID': 'NDD_SMR_genes_all_update_text_122474', 'Gene': 'CLASRP', 'topRSID': 'rs1560725', 'p_GWAS': 1.30512e-08, 'b_GWAS': 0.0506}, {'UUID': 'NDD_SMR_genes_all_update_text_637443', 'Gene': 'CLASRP', 'topRSID': 'rs1560725', 'p_GWAS': 1.30512e-08, 'b_GWAS': 0.0506}, {'UUID': 'NDD_SMR_genes_all_update_text_1503909', 'Gene': 'CLASRP', 'topRSID': 'rs1560725', 'p_GWAS': 1.30512e-08, 'b_GWAS': 0.0506}] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1066 | Q10 | Are there any PPM1B SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within PPM1B that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'PPM1B' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.58 | Q10 | Are there any MYOM2 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within MYOM2 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'MYOM2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1688 | Q10 | Are there any WRN SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within WRN that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'WRN' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1955 | Q10 | Are there any SLC6A19 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within SLC6A19 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'SLC6A19' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1218 | Q10 | Are there any ZNF187 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within ZNF187 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'ZNF187' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1680 | Q10 | Are there any RP11-573D15.2 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within RP11-573D15.2 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'RP11-573D15.2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1975 | Q10 | Are there any CTD-2009A10.1 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within CTD-2009A10.1 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'CTD-2009A10.1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.213 | Q10 | Are there any SLC6A11 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within SLC6A11 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'SLC6A11' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1534 | Q10 | Are there any NFKB2 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within NFKB2 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'NFKB2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1135 | Q10 | Are there any FAM181B SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within FAM181B that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'FAM181B' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.131 | Q10 | Are there any GUSB SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within GUSB that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'GUSB' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.819 | Q10 | Are there any BZRAP1-AS1 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within BZRAP1-AS1 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'BZRAP1-AS1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1282 | Q10 | Are there any SMIM15 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within SMIM15 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'SMIM15' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1872 | Q10 | Are there any ARID3B SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within ARID3B that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'ARID3B' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.438 | Q10 | Are there any SPPL2C SNPs that have a statistically significant association with Progressive supranuclear palsy? | Yes, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are at least 2 SPPL2C SNPs that are significantly associatied with Progressive supranuclear palsy:
• rs393152 (GWAS p-value: 8.30e-51; b-value: -1.652)
• rs1981997 (GWAS p-value: 1.79e-51; b-value: 1.715) | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'SPPL2C' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [{'UUID': 'NDD_SMR_genes_all_update_text_1194215', 'Gene': 'SPPL2C', 'topRSID': 'rs1981997', 'p_GWAS': 1.792216e-51, 'b_GWAS': 1.7146}, {'UUID': 'NDD_SMR_genes_all_update_text_1714154', 'Gene': 'SPPL2C', 'topRSID': 'rs1981997', 'p_GWAS': 1.792216e-51, 'b_GWAS': 1.7146}, {'UUID': 'NDD_SMR_genes_all_update_text_22216', 'Gene': 'SPPL2C', 'topRSID': 'rs393152', 'p_GWAS': 8.302968999999999e-51, 'b_GWAS': -1.6521}, {'UUID': 'NDD_SMR_genes_all_update_text_1154395', 'Gene': 'SPPL2C', 'topRSID': 'rs393152', 'p_GWAS': 8.302968999999999e-51, 'b_GWAS': -1.6521}] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.417 | Q10 | Are there any SASH1 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within SASH1 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'SASH1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1504 | Q10 | Are there any RP1-41P2.7 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within RP1-41P2.7 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'RP1-41P2.7' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.234 | Q10 | Are there any C1orf97 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within C1orf97 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'C1orf97' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1708 | Q10 | Are there any UCP1 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within UCP1 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'UCP1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.895 | Q10 | Are there any FLT1 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within FLT1 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'FLT1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1625 | Q10 | Are there any NOS1AP SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within NOS1AP that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'NOS1AP' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.699 | Q10 | Are there any CCDC148 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within CCDC148 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'CCDC148' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1769 | Q10 | Are there any AL035610.1 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within AL035610.1 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'AL035610.1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.301 | Q10 | Are there any MS4A3 SNPs that have a statistically significant association with Alzheimer's Disease? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are at least 4 MS4A3 SNPs that are significantly associatied with Alzheimer's Disease:
• rs554311 (GWAS p-value: 1.16e-12; b-value: 0.0647)
• rs539360 (GWAS p-value: 3.00e-12; b-value: -0.0628)
• rs471457 (GWAS p-value: 2.77e-12; b-value: -0.0629)
• rs1286162 (GWAS p-value: 1.72e-12; b-value: -0.0635) | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'MS4A3' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [{'UUID': 'NDD_SMR_genes_all_update_text_91388', 'Gene': 'MS4A3', 'topRSID': 'rs554311', 'p_GWAS': 1.161354e-12, 'b_GWAS': 0.0647}, {'UUID': 'NDD_SMR_genes_all_update_text_608692', 'Gene': 'MS4A3', 'topRSID': 'rs1286162', 'p_GWAS': 1.719125e-12, 'b_GWAS': -0.0635}, {'UUID': 'NDD_SMR_genes_all_update_text_608691', 'Gene': 'MS4A3', 'topRSID': 'rs471457', 'p_GWAS': 2.770717e-12, 'b_GWAS': -0.0629}, {'UUID': 'NDD_SMR_genes_all_update_text_608689', 'Gene': 'MS4A3', 'topRSID': 'rs539360', 'p_GWAS': 2.998855e-12, 'b_GWAS': -0.0628}] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1399 | Q10 | Are there any MGEA5 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within MGEA5 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'MGEA5' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1987 | Q10 | Are there any URAHP SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within URAHP that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'URAHP' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.102 | Q10 | Are there any ATF4P4 SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within ATF4P4 that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'ATF4P4' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.831 | Q10 | Are there any RP11-6N17.9 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within RP11-6N17.9 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'RP11-6N17.9' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.359 | Q10 | Are there any LOC389332 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within LOC389332 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'LOC389332' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.114 | Q10 | Are there any FAM213A SNPs that have a statistically significant association with Alzheimer's Disease? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are at least 2 FAM213A SNPs that are significantly associatied with Alzheimer's Disease:
• rs1870142 (GWAS p-value: 1.12e-08; b-value: 0.0514)
• rs4258322 (GWAS p-value: 1.28e-08; b-value: -0.0512) | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'FAM213A' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [{'UUID': 'NDD_SMR_genes_all_update_text_85777', 'Gene': 'FAM213A', 'topRSID': 'rs1870142', 'p_GWAS': 1.122409e-08, 'b_GWAS': 0.0514}, {'UUID': 'NDD_SMR_genes_all_update_text_572642', 'Gene': 'FAM213A', 'topRSID': 'rs4258322', 'p_GWAS': 1.278686e-08, 'b_GWAS': -0.0512}] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1440 | Q10 | Are there any NIPAL2 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within NIPAL2 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'NIPAL2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1840 | Q10 | Are there any ZNF611 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within ZNF611 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'ZNF611' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.952 | Q10 | Are there any C6orf165 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within C6orf165 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'C6orf165' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1186 | Q10 | Are there any ATF6 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within ATF6 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'ATF6' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.456 | Q10 | Are there any SERPINF2 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within SERPINF2 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'SERPINF2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.876 | Q10 | Are there any EPHA1-AS1 SNPs that have a statistically significant association with Alzheimer's Disease? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are at least 4 EPHA1-AS1 SNPs that are significantly associatied with Alzheimer's Disease:
• rs10226151 (GWAS p-value: 9.29e-12; b-value: 0.0559)
• rs75045569 (GWAS p-value: 2.73e-11; b-value: -0.0726)
• rs11769559 (GWAS p-value: 2.92e-16; b-value: -0.0695)
• rs3935067 (GWAS p-value: 1.08e-08; b-value: 0.0486) | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'EPHA1-AS1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [{'UUID': 'NDD_SMR_genes_all_update_text_1287997', 'Gene': 'EPHA1-AS1', 'topRSID': 'rs11769559', 'p_GWAS': 2.922788e-16, 'b_GWAS': -0.0695}, {'UUID': 'NDD_SMR_genes_all_update_text_1649764', 'Gene': 'EPHA1-AS1', 'topRSID': 'rs11769559', 'p_GWAS': 2.922788e-16, 'b_GWAS': -0.0695}, {'UUID': 'NDD_SMR_genes_all_update_text_75161', 'Gene': 'EPHA1-AS1', 'topRSID': 'rs10226151', 'p_GWAS': 9.291395e-12, 'b_GWAS': 0.0559}, {'UUID': 'NDD_SMR_genes_all_update_text_587067', 'Gene': 'EPHA1-AS1', 'topRSID': 'rs75045569', 'p_GWAS': 2.728039e-11, 'b_GWAS': -0.0726}, {'UUID': 'NDD_SMR_genes_all_update_text_1496073', 'Gene': 'EPHA1-AS1', 'topRSID': 'rs3935067', 'p_GWAS': 1.080092e-08, 'b_GWAS': 0.0486}] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1545 | Q10 | Are there any NDFIP1 SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within NDFIP1 that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'NDFIP1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1701 | Q10 | Are there any AC008731.1 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within AC008731.1 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'AC008731.1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1436 | Q10 | Are there any MED13 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within MED13 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'MED13' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.915 | Q10 | Are there any PPP1R9B SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within PPP1R9B that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'PPP1R9B' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.310 | Q10 | Are there any OVCH2 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within OVCH2 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'OVCH2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1257 | Q10 | Are there any SEPT7P2 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within SEPT7P2 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'SEPT7P2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1409 | Q10 | Are there any SLC13A5 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within SLC13A5 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'SLC13A5' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.618 | Q10 | Are there any LMO1 SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within LMO1 that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'LMO1' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1479 | Q10 | Are there any RP1-40E16.11 SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within RP1-40E16.11 that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'RP1-40E16.11' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.250 | Q10 | Are there any TIAM2 SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within TIAM2 that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'TIAM2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.734 | Q10 | Are there any EEF1E1-BLOC1S5 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within EEF1E1-BLOC1S5 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'EEF1E1-BLOC1S5' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.311 | Q10 | Are there any NRL SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within NRL that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'NRL' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.236 | Q10 | Are there any ZNF3 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within ZNF3 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'ZNF3' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.72 | Q10 | Are there any ULK4 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within ULK4 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'ULK4' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.896 | Q10 | Are there any SMPD4 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within SMPD4 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'SMPD4' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1754 | Q10 | Are there any HOXA-AS4 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within HOXA-AS4 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'HOXA-AS4' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.712 | Q10 | Are there any RP11-712L6.7 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within RP11-712L6.7 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'RP11-712L6.7' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1383 | Q10 | Are there any RP5-865N13.2 SNPs that have a statistically significant association with Alzheimer's Disease? | No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within RP5-865N13.2 that are significantly associated with Alzheimer's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'AD' AND Gene = 'RP5-865N13.2' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1329 | Q10 | Are there any AK4P3 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within AK4P3 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'AK4P3' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.624 | Q10 | Are there any RP11-281O15.4 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within RP11-281O15.4 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'RP11-281O15.4' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1464 | Q10 | Are there any SETD1A SNPs that have a statistically significant association with Parkinson's Disease? | Yes, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are at least 4 SETD1A SNPs that are significantly associatied with Parkinson's Disease:
• rs11150601 (GWAS p-value: 9.34e-10; b-value: -0.112)
• rs7200879 (GWAS p-value: 2.09e-09; b-value: -0.124)
• rs12934900 (GWAS p-value: 4.02e-11; b-value: -0.1215)
• rs7206511 (GWAS p-value: 2.11e-10; b-value: -0.1169) | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'SETD1A' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [{'UUID': 'NDD_SMR_genes_all_update_text_1435341', 'Gene': 'SETD1A', 'topRSID': 'rs12934900', 'p_GWAS': 4.022109e-11, 'b_GWAS': -0.1215}, {'UUID': 'NDD_SMR_genes_all_update_text_1563807', 'Gene': 'SETD1A', 'topRSID': 'rs7206511', 'p_GWAS': 2.107978e-10, 'b_GWAS': -0.1169}, {'UUID': 'NDD_SMR_genes_all_update_text_485446', 'Gene': 'SETD1A', 'topRSID': 'rs11150601', 'p_GWAS': 9.344708e-10, 'b_GWAS': -0.112}, {'UUID': 'NDD_SMR_genes_all_update_text_974662', 'Gene': 'SETD1A', 'topRSID': 'rs7200879', 'p_GWAS': 2.094052e-09, 'b_GWAS': -0.124}] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1556 | Q10 | Are there any PRR14 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within PRR14 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'PRR14' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.708 | Q10 | Are there any ATP23 SNPs that have a statistically significant association with Parkinson's Disease? | No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within ATP23 that are significantly associated with Parkinson's Disease. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PD' AND Gene = 'ATP23' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.1928 | Q10 | Are there any AC012363.7 SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis? | No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within AC012363.7 that are significantly associated with Amyotrophic Lateral Sclerosis. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'ALS' AND Gene = 'AC012363.7' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.614 | Q10 | Are there any C17orf105 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within C17orf105 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'C17orf105' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Q10.372 | Q10 | Are there any CTC-524C5.5 SNPs that have a statistically significant association with Progressive supranuclear palsy? | No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within CTC-524C5.5 that are significantly associated with Progressive supranuclear palsy. | SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
WHERE Disease = 'PSP' AND Gene = 'CTC-524C5.5' AND p_GWAS < 5e-8
ORDER BY p_GWAS
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Order By | GWAS Significance |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.